Davis DR, Kurti AN, Skelly JM, Redner R, White TJ, Higgins ST A review of the literature on contingency management in the treatment of substance use disorders, 2009-2014. Prev Med. 2016 Nov;92:36-46. doi: 10.1016/j.ypmed.2016.08.008. Epub 2016 Aug 8.
Hutchinson ML, Chisolm MS, Tuten M, Leoutsakos JM, Jones HE The efficacy of escalating and fixed contingency management reinforcement on illicit drug use in opioid-dependent pregnant women. Addict Disord Their Treat. 2012 Sep;11(3):150-153. doi: 10.1097/ADT.0b013e318264cf6d.
Packer RR, Howell DN, McPherson S, Roll JM Investigating reinforcer magnitude and reinforcer delay: a contingency management analog study. Exp Clin Psychopharmacol. 2012 Aug;20(4):287-92. doi: 10.1037/a0027802. Epub 2012 Jun 11.
Petry NM, Alessi SM, Barry D, Carroll KM Standard magnitude prize reinforcers can be as efficacious as larger magnitude reinforcers in cocaine-dependent methadone patients. J Consult Clin Psychol. 2015 Jun;83(3):464-72. doi: 10.1037/a0037888. Epub 2014 Sep 8.
Petry NM, Alessi SM, Marx J, Austin M, Tardif M Vouchers versus prizes: contingency management treatment of substance abusers in community settings. J Consult Clin Psychol. 2005 Dec;73(6):1005-14. doi: 10.1037/0022-006X.73.6.1005.
Petry NM, Barry D, Alessi SM, Rounsaville BJ, Carroll KM A randomized trial adapting contingency management targets based on initial abstinence status of cocaine-dependent patients. J Consult Clin Psychol. 2012 Apr;80(2):276-85. doi: 10.1037/a0026883. Epub 2012 Jan 9.
Petry NM, Martin B Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients. J Consult Clin Psychol. 2002 Apr;70(2):398-405. doi: 10.1037//0022-006x.70.2.398.
Prendergast ML, Podus D, Chang E, Urada D The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug Alcohol Depend. 2002 Jun 1;67(1):53-72. doi: 10.1016/s0376-8716(02)00014-5. Erratum In: Drug Alcohol Depend. 2006 Sep 1;84(1):133.
Rash CJ, Petry NM Contingency management treatments are equally efficacious for both sexes in intensive outpatient settings. Exp Clin Psychopharmacol. 2015 Oct;23(5):369-76. doi: 10.1037/pha0000035. Epub 2015 Jul 13.
Roll JM, Higgins ST, Badger GJ An experimental comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. J Appl Behav Anal. 1996 Winter;29(4):495-504; quiz 504-5. doi: 10.1901/jaba.1996.29-495.
Roll JM, Higgins ST A within-subject comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. Drug Alcohol Depend. 2000 Feb 1;58(1-2):103-9. doi: 10.1016/s0376-8716(99)00073-3.
Roll, John M , Huber, A., Sodano, R., Chudzynski, J.E., Moynier, E., Shoptaw, S. (2006). A Comparison of Five Reinforcement Schedules for Use in Contingency Management-Based Treatment of Methamphetamine Abuse. Psychological Record, 56(1), 67.
Romanowich P, Lamb RJ Effects of escalating and descending schedules of incentives on cigarette smoking in smokers without plans to quit. J Appl Behav Anal. 2010 Fall;43(3):357-67. doi: 10.1901/jaba.2010.43-357.
Romanowich P, Lamb RJ The effects of fixed versus escalating reinforcement schedules on smoking abstinence. J Appl Behav Anal. 2015 Spring;48(1):25-37. doi: 10.1002/jaba.185. Epub 2015 Jan 30.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
